Clinical Trial Update: Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating capecitabine in combination with immunotherapy versus immunotherapy alone in advanced renal cell carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Immunotherapy (unspecified)

Snippet

Sponsor: Central European Cooperative Oncology Group | Conditions: Renal Cell Cancer | Phase 3 | Status: TERMINATED